Moderna has experienced significant developments in recent months. Firstly, it has started rolling out its first
made-in-Canada COVID-19 vaccines this fall. It resolved its patent litigation with
Alnylam over COVID-19 vaccine delivery technology and reported an 8-fold jump in antibodies with their updated vaccine,
Spikevax. However, it also faced some setbacks as the
US ended some mRNA vaccine contracts, and
RFK Jr canceled $500m in mRNA vaccine development in the US. Despite this, Moderna’s stock rose as its updated COVID-19 jab showed a strong immune response. A series of investments and sales of Moderna's stock notably influenced the market dynamic. Furthermore, Moderna showed promising results from its
mRNA flu vaccine trial. This follows on from the FDA granting the nod for Moderna's next-gen COVID-19 vaccine targeting the LP.8.1 variant. The company is also expanding into
Oncology with a Pan-Tumor Vaccine. However, Moderna has faced significant scrutiny over vaccine safety, with concerns impacting its investment story. It received full US approval for its COVID-19 shot in
at-risk children aged 6 months and older.
Moderna MRNA News Analytics from Fri, 17 Jan 2025 08:00:00 GMT to Sun, 21 Sep 2025 00:07:11 GMT -
Rating 5
- Innovation 8
- Information 8
- Rumor 3
